Evariste is building the next generation of precision medicines using mathematical modelling and machine learning to identify novel targets and generate first-in-class, best-in-class small molecule candidates.We have a strong pipeline of assets ranging from early discovery to late-preclinical compounds undergoing proof-of-concept studies - all of which have been rapidly developed using our AI-powered Target ID, Hit ID and Hit-to-Candidate platforms.